What is Bicara Therapeutics's short-term investments?

Bicara Therapeutics (BCAX) reported short-term investments of $216.29M in Q1 2026.

What does short-term investments mean?

Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.

Bicara Therapeutics BCAX Short-Term Investments

Short-Term Investments at other companies

ArriVent BioPharma, Inc.AVBP

$264.28M+109%

Arcus BiosciencesRCUS

$621M-22.9%

Syndax PharmaceuticalsSNDX

$221.17M-38.3%

Nuvation BioNUVB

$408.34M-1.3%

Viridian Therapeutics, Inc.VRDN

$585.84M+12.6%

Summit TherapeuticsSMMT

$492.22M+229%

Other financials

Income statement

See full

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

EPS (diluted)-$0.93-36.8%

Balance sheet

See full

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Cash flow

See full

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Valuation

See full

Market cap$1.64B+81.4%

Enterprise value$1.32B+288%

Returns & leverage

See full

Return on equity-32.3%—

Debt / equity0×0.0×

Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bicara Therapeutics's short-term investments?: Bicara Therapeutics (BCAX) reported short-term investments of $216.29M in Q1 2026.
What does short-term investments mean?: Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.